Contemporary OB/GYN week in review: STI prevention, abortion travel, and more
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Contemporary OB/GYN week in review: STI prevention, abortion travel, and more
Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, June 03 - Friday, June 07, 2024), and click each link to read and watch anything you may have missed.
1.) CDC suggests doxycycline postexposure prophylaxis for STI prevention
Following evidence from recent studies, the Centers for Disease Control and Prevention has recommended the use of doxycycline postexposure prophylaxis in sexual health among certain populations.
Click here for the full article.
2.) Out-of-state abortion travel and care delays increased in Washington post-Dobbs
A study revealed that the Dobbs v Jackson Women’s Health Organization decision has led to more out-of-state abortions and longer gestation periods in states such as Washington with legalized abortion.
Click here for the full article.
3.) Benefits of extended combined hormonal contraceptive regimens
Extended combined hormonal contraceptive regimens, which include prolonged active hormone use and shorter hormone-free intervals, offer increased contraceptive efficacy, reduced menstrual symptoms, and improved management of withdrawal bleeding compared to traditional cyclic use.
Click here for the full article.
4.) Does menopause really cause depression?
Though studies on the prevalence of depression during menopause vary, for those experiencing the symptoms, quality of life can be severely compromised.
Click here for the full article.
5.) COVID-19 and pregnancy: An update
Four years into the COVID-19 pandemic, what we know about the novel coronavirus and pregnancy has evolved. Find out what we've learned thus far.
FDA adds boxed warning to fezolinetant for rare serious liver injury
Published: December 17th 2024 | Updated: December 17th 2024The FDA has added a boxed warning for fezolinetant (VEOZAH; Astellas), highlighting the rare occurrence of serious liver injury in patients taking the menopause treatment.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More
